<?xml version="1.0" encoding="UTF-8"?>

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="HIV.C"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p>This case-insensitive code system <code>http://worldhealthorganization.github.io/smart/CodeSystem/HIV.C</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">DE1<a name="HIV.C-DE1"> </a></td><td>Reason for PrEP visit</td><td>Client's reason for the prevention visit</td></tr><tr><td style="white-space:nowrap">DE2<a name="HIV.C-DE2"> </a></td><td>First time counselling on PrEP</td><td>The client is interested in discussing pre-exposure prophylaxis (PrEP) for the first time</td></tr><tr><td style="white-space:nowrap">DE3<a name="HIV.C-DE3"> </a></td><td>Follow-up appointment for PrEP</td><td>Client is at a follow-up or refill pre-exposure prophylaxis (PrEP) appointment</td></tr><tr><td style="white-space:nowrap">DE4<a name="HIV.C-DE4"> </a></td><td>Restarting PrEP</td><td>Client has previously taken pre-exposure prophylaxis (PrEP) and may like to restart taking it</td></tr><tr><td style="white-space:nowrap">DE5<a name="HIV.C-DE5"> </a></td><td>Counselling on PEP</td><td>Counselling on post-exposure prophylaxis (PEP)</td></tr><tr><td style="white-space:nowrap">DE6<a name="HIV.C-DE6"> </a></td><td>Unscheduled visit for side effects</td><td>Patient visit for management of side effects related to PrEP</td></tr><tr><td style="white-space:nowrap">DE7<a name="HIV.C-DE7"> </a></td><td>3-month PrEP visit</td><td>Client is visiting for the recommended 3-month pre-exposure prophylaxis (PrEP) visit</td></tr><tr><td style="white-space:nowrap">DE8<a name="HIV.C-DE8"> </a></td><td>Contact with and (suspected) exposure to HIV</td><td>The client had suspected or known exposure to HIV</td></tr><tr><td style="white-space:nowrap">DE9<a name="HIV.C-DE9"> </a></td><td>Date/time of suspected exposure to HIV</td><td>When the suspect exposure to HIV took place</td></tr><tr><td style="white-space:nowrap">DE10<a name="HIV.C-DE10"> </a></td><td>Currently on PrEP</td><td>The client is currently taking PrEP. Oral pre-exposure prophylaxis (PrEP) of HIV is the use of ARV drugs by people who are not infected with HIV to block the acquisition of HIV.</td></tr><tr><td style="white-space:nowrap">DE11<a name="HIV.C-DE11"> </a></td><td>PrEP dosing type</td><td>Way in which pre-exposure prophylaxis (PrEP) is taken (daily or event-driven)</td></tr><tr><td style="white-space:nowrap">DE12<a name="HIV.C-DE12"> </a></td><td>Daily oral PrEP</td><td>Pre-exposure prophylaxis (PrEP) is taken every day</td></tr><tr><td style="white-space:nowrap">DE13<a name="HIV.C-DE13"> </a></td><td>Event-driven PrEP (2+1+1)</td><td>Event-driven pre-exposure prophylaxis (PrEP) is taken on an even-driven basis (2+1+1)</td></tr><tr><td style="white-space:nowrap">DE14<a name="HIV.C-DE14"> </a></td><td>Other PrEP dosing type</td><td>Other PrEP dosing type</td></tr><tr><td style="white-space:nowrap">DE15<a name="HIV.C-DE15"> </a></td><td>Other PrEP dosing type (specify)</td><td>Other PrEP dosing type (specify)</td></tr><tr><td style="white-space:nowrap">DE16<a name="HIV.C-DE16"> </a></td><td>Used event-driven PrEP for at risk exposures over the past 3 months</td><td>Client reports taking ED-PrEP for at risk exposures over a 3-month period</td></tr><tr><td style="white-space:nowrap">DE17<a name="HIV.C-DE17"> </a></td><td>Current PrEP regimen</td><td>HIV pre-exposure prophylaxis (PrEP) regimen</td></tr><tr><td style="white-space:nowrap">DE18<a name="HIV.C-DE18"> </a></td><td>TDF + FTC</td><td>Treated with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)</td></tr><tr><td style="white-space:nowrap">DE19<a name="HIV.C-DE19"> </a></td><td>TDF</td><td>Treated with single-agent tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)</td></tr><tr><td style="white-space:nowrap">DE20<a name="HIV.C-DE20"> </a></td><td>TDF + 3TC</td><td>Treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)</td></tr><tr><td style="white-space:nowrap">DE21<a name="HIV.C-DE21"> </a></td><td>Other TDF-based regimen</td><td>Treated with other tenofovir disoproxil fumarate (TDF)-based regimen (oral PrEP)</td></tr><tr><td style="white-space:nowrap">DE22<a name="HIV.C-DE22"> </a></td><td>Dapivirine vaginal ring (DVR)</td><td>Dapivirine vaginal ring (DVR) for HIV prevention</td></tr><tr><td style="white-space:nowrap">DE23<a name="HIV.C-DE23"> </a></td><td>CAB-LA</td><td>Long-acting injectable cabotegravir</td></tr><tr><td style="white-space:nowrap">DE24<a name="HIV.C-DE24"> </a></td><td>Experience with PrEP</td><td>The client's experience in taking PrEP</td></tr><tr><td style="white-space:nowrap">DE25<a name="HIV.C-DE25"> </a></td><td>First-time user</td><td>The client has never used pre-exposure prophylaxis (PrEP) before (naive)</td></tr><tr><td style="white-space:nowrap">DE26<a name="HIV.C-DE26"> </a></td><td>Continuing user</td><td>The client has used PrEP before and is continuing to use PrEP</td></tr><tr><td style="white-space:nowrap">DE27<a name="HIV.C-DE27"> </a></td><td>Restarting following a period of not taking PrEP</td><td>The client is restarting PrEP following a period of not taking PrEP</td></tr><tr><td style="white-space:nowrap">DE28<a name="HIV.C-DE28"> </a></td><td>PrEP start date</td><td>The date on which the client started or restarted pre-exposure prophylaxis (PrEP)</td></tr><tr><td style="white-space:nowrap">DE29<a name="HIV.C-DE29"> </a></td><td>Stopped PrEP</td><td>Client stopped taking pre-exposure prophylaxis (PrEP)</td></tr><tr><td style="white-space:nowrap">DE30<a name="HIV.C-DE30"> </a></td><td>Date PrEP stopped</td><td>Date client stopped taking pre-exposure prophylaxis (PrEP)</td></tr><tr><td style="white-space:nowrap">DE31<a name="HIV.C-DE31"> </a></td><td>PEP history</td><td>The client's history in taking post-exposure prophylaxis (PEP) for HIV prevention</td></tr><tr><td style="white-space:nowrap">DE32<a name="HIV.C-DE32"> </a></td><td>First-time user</td><td>The client has never used post-exposure prophylaxis (PEP) before</td></tr><tr><td style="white-space:nowrap">DE33<a name="HIV.C-DE33"> </a></td><td>Repeat user</td><td>The client has used post-exposure prophylaxis (PEP) before</td></tr><tr><td style="white-space:nowrap">DE34<a name="HIV.C-DE34"> </a></td><td>Date(s) of past PEP use</td><td>Dates when the client previously used post-exposure prophylaxis (PEP)</td></tr><tr><td style="white-space:nowrap">DE35<a name="HIV.C-DE35"> </a></td><td>Date client completes PEP course</td><td>Date client completes PEP course</td></tr><tr><td style="white-space:nowrap">DE36<a name="HIV.C-DE36"> </a></td><td>Signs of substantial risk of HIV infection</td><td>Signs the client is at a substantial risk of HIV infection</td></tr><tr><td style="white-space:nowrap">DE37<a name="HIV.C-DE37"> </a></td><td>No condom use during sex with more than one partner in the past 6 months</td><td>Recent vaginal or anal sexual intercourse without a condom with more than one partner</td></tr><tr><td style="white-space:nowrap">DE38<a name="HIV.C-DE38"> </a></td><td>STI in the past 6 months</td><td>A recent history (in the last 6 months) of a sexually transmitted infection (STI ) by laboratory testing, self-report or syndromic STI treatment</td></tr><tr><td style="white-space:nowrap">DE39<a name="HIV.C-DE39"> </a></td><td>A sexual partner in the past 6 months had one or more HIV risk factors</td><td>A recent sex partner of the client had HIV risk factors</td></tr><tr><td style="white-space:nowrap">DE40<a name="HIV.C-DE40"> </a></td><td>PrEP requested by client</td><td>Client is requesting PrEP, reflecting a decision-making process has already taken place and suggesting of substantial risk of HIV</td></tr><tr><td style="white-space:nowrap">DE41<a name="HIV.C-DE41"> </a></td><td>Pregnancy intention in serodiscordant partnerships</td><td>Client's intention or desire in the next year to either become pregnant or prevent a future pregnancy (in serodiscordant partnerships)</td></tr><tr><td style="white-space:nowrap">DE42<a name="HIV.C-DE42"> </a></td><td>Yes, I want to become pregnant</td><td>Client intends to become pregnant</td></tr><tr><td style="white-space:nowrap">DE43<a name="HIV.C-DE43"> </a></td><td>I'm OK either way</td><td>Client is not intending to become pregnant, but would not be adverse to becoming pregnant</td></tr><tr><td style="white-space:nowrap">DE44<a name="HIV.C-DE44"> </a></td><td>No, I don't want to become pregnant</td><td>Client does not intend to become pregnant</td></tr><tr><td style="white-space:nowrap">DE45<a name="HIV.C-DE45"> </a></td><td>Unsure</td><td>Client is unsure or undecided about her pregnancy intentions</td></tr><tr><td style="white-space:nowrap">DE46<a name="HIV.C-DE46"> </a></td><td>Acute HIV infection symptoms</td><td>Symptoms that could suggest an acute HIV infection</td></tr><tr><td style="white-space:nowrap">DE47<a name="HIV.C-DE47"> </a></td><td>Fever</td><td>Client's symptoms include a fever</td></tr><tr><td style="white-space:nowrap">DE48<a name="HIV.C-DE48"> </a></td><td>Sore throat</td><td>Client's symptoms include a sore throat</td></tr><tr><td style="white-space:nowrap">DE49<a name="HIV.C-DE49"> </a></td><td>Aches</td><td>Client's symptoms include aches</td></tr><tr><td style="white-space:nowrap">DE50<a name="HIV.C-DE50"> </a></td><td>Pains</td><td>Client's symptoms include pains</td></tr><tr><td style="white-space:nowrap">DE51<a name="HIV.C-DE51"> </a></td><td>Swollen glands</td><td>Client's symptoms include swollen glands</td></tr><tr><td style="white-space:nowrap">DE52<a name="HIV.C-DE52"> </a></td><td>Mouth sores</td><td>Client's symptoms include a mouth sores</td></tr><tr><td style="white-space:nowrap">DE53<a name="HIV.C-DE53"> </a></td><td>Headaches</td><td>Client's symptoms include a headaches</td></tr><tr><td style="white-space:nowrap">DE54<a name="HIV.C-DE54"> </a></td><td>Rash</td><td>Client's symptoms include a rash</td></tr><tr><td style="white-space:nowrap">DE55<a name="HIV.C-DE55"> </a></td><td>Sex partner's HIV treatment status</td><td>Treatment adherence of client's sex partner for partners that are HIV-positive</td></tr><tr><td style="white-space:nowrap">DE56<a name="HIV.C-DE56"> </a></td><td>Not on ART</td><td>Sex partner is HIV-positive and not on ART</td></tr><tr><td style="white-space:nowrap">DE57<a name="HIV.C-DE57"> </a></td><td>On ART less than 6 months</td><td>Sex partner is HIV-positive and is on ART less than 6 months. ART may take up to 6 months to suppress viral load. In studies of serodiscordant couples, pre-exposure prophylaxis (PrEP) has provided a useful bridge to full viral suppression by the partner during that time.</td></tr><tr><td style="white-space:nowrap">DE58<a name="HIV.C-DE58"> </a></td><td>Partner has suspected low adherence to ART</td><td>Sex partner is HIV-positive and is suspected to have low adherence to ART. There have been gaps in the partner's treatment adherence or the couple is not communicating openly about treatment adherence and viral load test results.</td></tr><tr><td style="white-space:nowrap">DE59<a name="HIV.C-DE59"> </a></td><td>Partner is not virally suppressed</td><td>Sex partner is HIV-positive and not virally suppressed</td></tr><tr><td style="white-space:nowrap">DE60<a name="HIV.C-DE60"> </a></td><td>Partner is virally suppressed and has been on ART for 6 months or more</td><td>Sex partner is HIV-positive and virally suppressed with 6 months or more on ART</td></tr><tr><td style="white-space:nowrap">DE61<a name="HIV.C-DE61"> </a></td><td>Suitable for PrEP</td><td>The client is suitable for PrEP</td></tr><tr><td style="white-space:nowrap">DE62<a name="HIV.C-DE62"> </a></td><td>Offered PrEP</td><td>After being evaluated as suitable for PrEP, the client was offered PrEP</td></tr><tr><td style="white-space:nowrap">DE63<a name="HIV.C-DE63"> </a></td><td>Screenings and diagnostics for PrEP users</td><td>Listing of tests for clients on or starting pre-exposure prophylaxis (PrEP) that may be recommended or should be considered</td></tr><tr><td style="white-space:nowrap">DE64<a name="HIV.C-DE64"> </a></td><td>Serum creatinine test</td><td>Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min)</td></tr><tr><td style="white-space:nowrap">DE65<a name="HIV.C-DE65"> </a></td><td>Hepatitis B test</td><td>Hepatitis B test recommended for client</td></tr><tr><td style="white-space:nowrap">DE66<a name="HIV.C-DE66"> </a></td><td>Hepatitis C test</td><td>Hepatitis C test recommended for client</td></tr><tr><td style="white-space:nowrap">DE67<a name="HIV.C-DE67"> </a></td><td>Syphilis test</td><td>Syphilis test recommended for client</td></tr><tr><td style="white-space:nowrap">DE68<a name="HIV.C-DE68"> </a></td><td>Other screening for STIs</td><td>Other STI screening recommended for client</td></tr><tr><td style="white-space:nowrap">DE69<a name="HIV.C-DE69"> </a></td><td>Pregnancy testing</td><td>Pregnancy testing for client</td></tr><tr><td style="white-space:nowrap">DE70<a name="HIV.C-DE70"> </a></td><td>Review vaccination history</td><td>Review vaccination history recommended for client</td></tr><tr><td style="white-space:nowrap">DE71<a name="HIV.C-DE71"> </a></td><td>Serum creatinine test date</td><td>Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min)</td></tr><tr><td style="white-space:nowrap">DE72<a name="HIV.C-DE72"> </a></td><td>Serum creatinine test result</td><td>Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min).</td></tr><tr><td style="white-space:nowrap">DE73<a name="HIV.C-DE73"> </a></td><td>Date medications dispensed</td><td>Date the client was dispensed medications</td></tr><tr><td style="white-space:nowrap">DE74<a name="HIV.C-DE74"> </a></td><td>Date medications prescribed</td><td>Date the client was prescribed medications</td></tr><tr><td style="white-space:nowrap">DE75<a name="HIV.C-DE75"> </a></td><td>Medications prescribed</td><td>Medications the client was prescribed</td></tr><tr><td style="white-space:nowrap">DE76<a name="HIV.C-DE76"> </a></td><td>PrEP for HIV prevention</td><td>Client was prescribed pre-exposure prophylaxis (PrEP) for HIV prevention</td></tr><tr><td style="white-space:nowrap">DE77<a name="HIV.C-DE77"> </a></td><td>PEP for HIV prevention</td><td>Client was prescribed post-exposure prophylaxis (PEP) for HIV prevention</td></tr><tr><td style="white-space:nowrap">DE78<a name="HIV.C-DE78"> </a></td><td>Other</td><td>Client was prescribed other medications</td></tr><tr><td style="white-space:nowrap">DE79<a name="HIV.C-DE79"> </a></td><td>Other (specify)</td><td>Client was prescribed other medications (specify)</td></tr><tr><td style="white-space:nowrap">DE80<a name="HIV.C-DE80"> </a></td><td>PrEP product prescribed</td><td>PrEP product that the client was prescribed</td></tr><tr><td style="white-space:nowrap">DE81<a name="HIV.C-DE81"> </a></td><td>Oral PrEP</td><td>Client was prescribed oral PrEP</td></tr><tr><td style="white-space:nowrap">DE82<a name="HIV.C-DE82"> </a></td><td>Dapivirine vaginal ring (DVR)</td><td>Client was prescribed dapivirine vaginal ring (DVR)</td></tr><tr><td style="white-space:nowrap">DE83<a name="HIV.C-DE83"> </a></td><td>CAB-LA</td><td>Client was prescribed long-acting cabotegravir (CAB-LA)</td></tr><tr><td style="white-space:nowrap">DE84<a name="HIV.C-DE84"> </a></td><td>Other</td><td>Client was prescribed other PrEP product</td></tr><tr><td style="white-space:nowrap">DE85<a name="HIV.C-DE85"> </a></td><td>Other (specify)</td><td>Client was prescribed other PrEP product (specify)</td></tr><tr><td style="white-space:nowrap">DE86<a name="HIV.C-DE86"> </a></td><td>Date PrEP prescribed</td><td>Date client was prescribed PrEP, including initial prescription and repeats</td></tr><tr><td style="white-space:nowrap">DE87<a name="HIV.C-DE87"> </a></td><td>Date PrEP dispensed</td><td>Date client was dispensed PrEP</td></tr><tr><td style="white-space:nowrap">DE88<a name="HIV.C-DE88"> </a></td><td>Volume of PrEP product prescribed/dispensed</td><td>Volume of PrEP product the client was prescribed or dispensed (for example, number of pills, number of devices)</td></tr><tr><td style="white-space:nowrap">DE89<a name="HIV.C-DE89"> </a></td><td>Date PEP prescribed</td><td>Date the client was prescribed PEP</td></tr><tr><td style="white-space:nowrap">DE90<a name="HIV.C-DE90"> </a></td><td>Date PEP course completion</td><td>Date client completes PEP course</td></tr><tr><td style="white-space:nowrap">DE91<a name="HIV.C-DE91"> </a></td><td>Preferred PEP backbone regimen</td><td>Preferred backbone regimen for PEP</td></tr><tr><td style="white-space:nowrap">DE92<a name="HIV.C-DE92"> </a></td><td>TDF + 3TC</td><td>Preferred backbone containing tenofovir disoproxil fumarate and lamivudine</td></tr><tr><td style="white-space:nowrap">DE93<a name="HIV.C-DE93"> </a></td><td>TDF + FTC</td><td>Preferred backbone containing tenofovir disoproxil fumarate and emtricitabine</td></tr><tr><td style="white-space:nowrap">DE94<a name="HIV.C-DE94"> </a></td><td>AZT + 3TC</td><td>Preferred backbone containing zidovudine and lamivudine</td></tr><tr><td style="white-space:nowrap">DE95<a name="HIV.C-DE95"> </a></td><td>Alternative PEP backbone regimen</td><td>Alternative backbone regimen for PEP</td></tr><tr><td style="white-space:nowrap">DE96<a name="HIV.C-DE96"> </a></td><td>ABC + 3TC</td><td>Alternative backbone containing abacavir and lamivudine</td></tr><tr><td style="white-space:nowrap">DE97<a name="HIV.C-DE97"> </a></td><td>TDF + 3TC</td><td>Alternative backbone containing tenofovir disoproxil fumarate and lamivudine</td></tr><tr><td style="white-space:nowrap">DE98<a name="HIV.C-DE98"> </a></td><td>TDF + FTC</td><td>Alternative backbone containing tenofovir disoproxil fumarate and emtricitabine</td></tr><tr><td style="white-space:nowrap">DE99<a name="HIV.C-DE99"> </a></td><td>Preferred third PEP drug</td><td>Preferred third drug for PEP</td></tr><tr><td style="white-space:nowrap">DE100<a name="HIV.C-DE100"> </a></td><td>DTG</td><td>Preferred third drug of dolutegravir</td></tr><tr><td style="white-space:nowrap">DE101<a name="HIV.C-DE101"> </a></td><td>Alternative third PEP drug</td><td>Alternative third drug for PEP</td></tr><tr><td style="white-space:nowrap">DE102<a name="HIV.C-DE102"> </a></td><td>ATV/r</td><td>Alternative third drug of atazanavir/ritonavir (ATV/r)</td></tr><tr><td style="white-space:nowrap">DE103<a name="HIV.C-DE103"> </a></td><td>DRV/r</td><td>Alternative third drug of darunavir/ritonavir (DRV/r)</td></tr><tr><td style="white-space:nowrap">DE104<a name="HIV.C-DE104"> </a></td><td>LPV/r</td><td>Alternative third drug of lopinavir/ritonavir (LPV/r)</td></tr><tr><td style="white-space:nowrap">DE105<a name="HIV.C-DE105"> </a></td><td>RAL</td><td>Alternative third drug of raltegravir (RAL)</td></tr><tr><td style="white-space:nowrap">DE106<a name="HIV.C-DE106"> </a></td><td>Estimated creatinine clearance</td><td>Estimated creatinine clearance of the client returned from lab in mL/min</td></tr><tr><td style="white-space:nowrap">DE107<a name="HIV.C-DE107"> </a></td><td>Sex factor for estimating creatinine clearance</td><td>Value used for gender for calculating creatinine clearance if required. For transgender populations, the sex at birth is used in the Cockcroft-Gault equation if the person is not using hormone therapy; among transgender populations using hormone therapy for more than three months, the current gender can be used.</td></tr><tr><td style="white-space:nowrap">DE108<a name="HIV.C-DE108"> </a></td><td>Male</td><td>Male client</td></tr><tr><td style="white-space:nowrap">DE109<a name="HIV.C-DE109"> </a></td><td>Female</td><td>Female client</td></tr><tr><td style="white-space:nowrap">DE110<a name="HIV.C-DE110"> </a></td><td>Estimated creatinine clearance (Cockcroft–Gault equation)</td><td>If the laboratory does not have the capacity to estimate creatinine clearance, the provider can use the Cockcroft–Gault equation to calculate estimated creatinine clearance based on measured serum creatinine, the client’s sex at birth, age and estimated lean body weight.</td></tr><tr><td style="white-space:nowrap">DE111<a name="HIV.C-DE111"> </a></td><td>Date of sample collection</td><td>Date when the specimen was collected</td></tr><tr><td style="white-space:nowrap">DE112<a name="HIV.C-DE112"> </a></td><td>Contraindications to PrEP usage</td><td>Listing of contraindications to pre-exposure prophylaxis (PrEP)</td></tr><tr><td style="white-space:nowrap">DE113<a name="HIV.C-DE113"> </a></td><td>Tenofovir disoproxil fumarate (TDF) allergy or contraindication</td><td>Allergy to pre-exposure prophylaxis (PrEP) tenofovir disoproxil fumarate (TDF)</td></tr><tr><td style="white-space:nowrap">DE114<a name="HIV.C-DE114"> </a></td><td>HIV-positive</td><td>Client is HIV-positive</td></tr><tr><td style="white-space:nowrap">DE115<a name="HIV.C-DE115"> </a></td><td>Low estimated creatinine clearance</td><td>Estimated creatinine clearance of less than 60 ml/min (if known)</td></tr><tr><td style="white-space:nowrap">DE116<a name="HIV.C-DE116"> </a></td><td>Acute HIV infection symptoms</td><td>Symptoms that could suggest an acute HIV infection</td></tr><tr><td style="white-space:nowrap">DE117<a name="HIV.C-DE117"> </a></td><td>Probable recent exposure to HIV</td><td>When the client is reported to have had probable recent exposure to HIV</td></tr><tr><td style="white-space:nowrap">DE118<a name="HIV.C-DE118"> </a></td><td>Other allergy or contraindication to a medicine in the PrEP regimen</td><td>Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen</td></tr><tr><td style="white-space:nowrap">DE119<a name="HIV.C-DE119"> </a></td><td>Other allergy or contraindication to a medicine in the PrEP regimen (specify)</td><td>Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen (specify)</td></tr><tr><td style="white-space:nowrap">DE120<a name="HIV.C-DE120"> </a></td><td>Prescribed PrEP at initial visit</td><td>Client was prescribed pre-exposure prophylaxis (PrEP) on a first visit</td></tr><tr><td style="white-space:nowrap">DE121<a name="HIV.C-DE121"> </a></td><td>Number of days prescribed</td><td>Days of medication client has been prescribed</td></tr><tr><td style="white-space:nowrap">DE122<a name="HIV.C-DE122"> </a></td><td>PrEP regimen prescribed</td><td>HIV pre-exposure prophylaxis (PrEP) regimen prescribed</td></tr><tr><td style="white-space:nowrap">DE123<a name="HIV.C-DE123"> </a></td><td>Adherence counselling provided</td><td>Whether adherence counselling was provided</td></tr><tr><td style="white-space:nowrap">DE124<a name="HIV.C-DE124"> </a></td><td>Date/time of follow-up appointment</td><td>Date the client is to return for monitoring, re-supply, or any other reason</td></tr><tr><td style="white-space:nowrap">DE125<a name="HIV.C-DE125"> </a></td><td>Type of follow-up appointment</td><td>Type of follow-up appointment for testing services</td></tr><tr><td style="white-space:nowrap">DE126<a name="HIV.C-DE126"> </a></td><td>Retesting for HIV</td><td>Retesting follow-up appointment</td></tr><tr><td style="white-space:nowrap">DE127<a name="HIV.C-DE127"> </a></td><td>Follow-up appointment for PrEP</td><td>Retesting follow-up appointment</td></tr><tr><td style="white-space:nowrap">DE128<a name="HIV.C-DE128"> </a></td><td>Other</td><td>Other reason for the follow-up appointment</td></tr><tr><td style="white-space:nowrap">DE129<a name="HIV.C-DE129"> </a></td><td>Other (specify)</td><td>Other reason for the follow-up appointment (specify)</td></tr><tr><td style="white-space:nowrap">DE130<a name="HIV.C-DE130"> </a></td><td>Linked to enrolment in care and ART initiation</td><td>Linkage made from HIV testing to enrolment in care following an HIV diagnosis</td></tr><tr><td style="white-space:nowrap">DE131<a name="HIV.C-DE131"> </a></td><td>Prevention services offered and referrals</td><td>Offer or refer to prevention services</td></tr><tr><td style="white-space:nowrap">DE132<a name="HIV.C-DE132"> </a></td><td>Male and female condoms and condom-compatible lubricants offered</td><td>Offer male and female condoms and condom-compatible lubricants</td></tr><tr><td style="white-space:nowrap">DE133<a name="HIV.C-DE133"> </a></td><td>Voluntary medical male circumcision (VMMC) referral</td><td>Offer referral for VMMC services</td></tr><tr><td style="white-space:nowrap">DE134<a name="HIV.C-DE134"> </a></td><td>Harm reduction for people who inject drugs</td><td>Offer or refer to harm reduction for people who inject drugs (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management) services</td></tr><tr><td style="white-space:nowrap">DE135<a name="HIV.C-DE135"> </a></td><td>Behavioural interventions to support risk reduction</td><td>Offer or refer to services for behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations</td></tr><tr><td style="white-space:nowrap">DE136<a name="HIV.C-DE136"> </a></td><td>Date provided condoms</td><td>Date client was provided with condoms</td></tr><tr><td style="white-space:nowrap">DE137<a name="HIV.C-DE137"> </a></td><td>Condoms distributed</td><td>Number of condoms given to the client, if any were distributed</td></tr><tr><td style="white-space:nowrap">DE138<a name="HIV.C-DE138"> </a></td><td>Condom type</td><td>Type of condom provided to client</td></tr><tr><td style="white-space:nowrap">DE139<a name="HIV.C-DE139"> </a></td><td>Male condom</td><td>Male condoms were provided to the client</td></tr><tr><td style="white-space:nowrap">DE140<a name="HIV.C-DE140"> </a></td><td>Female condom</td><td>Female condoms were provided to the client</td></tr><tr><td style="white-space:nowrap">DE141<a name="HIV.C-DE141"> </a></td><td>HIV self-test kits accepted</td><td>Whether any HIV self-test kits were given to the client</td></tr><tr><td style="white-space:nowrap">DE142<a name="HIV.C-DE142"> </a></td><td>Number of HIV self-test kits distributed</td><td>Number of HIV self-test kits distributed to the client</td></tr><tr><td style="white-space:nowrap">DE143<a name="HIV.C-DE143"> </a></td><td>HIV self-test distributed for use by</td><td>Whom the client plans to give the HIV self-test kit (self, sexual partner, social contact, etc.)</td></tr><tr><td style="white-space:nowrap">DE144<a name="HIV.C-DE144"> </a></td><td>Self</td><td>Client plans to use the self-test kit</td></tr><tr><td style="white-space:nowrap">DE145<a name="HIV.C-DE145"> </a></td><td>Family member</td><td>Client plans to give the self-test kit to a family member to use</td></tr><tr><td style="white-space:nowrap">DE146<a name="HIV.C-DE146"> </a></td><td>Drug-injecting partner</td><td>Client plans to give the self-test kit to a drug-injecting partner</td></tr><tr><td style="white-space:nowrap">DE147<a name="HIV.C-DE147"> </a></td><td>Sexual partner</td><td>Client plans to give the self-test kit to a sexual partner</td></tr><tr><td style="white-space:nowrap">DE148<a name="HIV.C-DE148"> </a></td><td>Social contact</td><td>Client plans to give the self-test kit to a social contact</td></tr><tr><td style="white-space:nowrap">DE149<a name="HIV.C-DE149"> </a></td><td>Sexual and reproductive health integrated services</td><td>Offer or refer to sexual and reproductive health services</td></tr><tr><td style="white-space:nowrap">DE150<a name="HIV.C-DE150"> </a></td><td>Contraception and family planning</td><td>Offer contraception and family planning services</td></tr><tr><td style="white-space:nowrap">DE151<a name="HIV.C-DE151"> </a></td><td>Check pregnancy status</td><td>Check woman's pregnancy status</td></tr><tr><td style="white-space:nowrap">DE152<a name="HIV.C-DE152"> </a></td><td>Prevent mother-to-child transmission</td><td>Offer services (counselling) to help prevent of mother-to-child transmission</td></tr><tr><td style="white-space:nowrap">DE153<a name="HIV.C-DE153"> </a></td><td>Cervical cancer screening and treatment</td><td>Offer cervical cancer screening and treatment services</td></tr><tr><td style="white-space:nowrap">DE154<a name="HIV.C-DE154"> </a></td><td>Anal cancer screening (for men who have sex with men)</td><td>Offer anal cancer screening (for men who have sex with men) services</td></tr><tr><td style="white-space:nowrap">DE155<a name="HIV.C-DE155"> </a></td><td>STI testing and treatment</td><td>Offer STI testing and treatment services</td></tr><tr><td style="white-space:nowrap">DE156<a name="HIV.C-DE156"> </a></td><td>HIV testing for partners and biological children</td><td>Offer testing for all partners and biological children of positive cases (includes partner services and index case testing), as well as partners and social contacts of people from key populations, where appropriate</td></tr><tr><td style="white-space:nowrap">DE157<a name="HIV.C-DE157"> </a></td><td>Offer other clinical services</td><td>Other clinical services offered or referrals given to the client</td></tr><tr><td style="white-space:nowrap">DE158<a name="HIV.C-DE158"> </a></td><td>Assessment and provision of vaccinations</td><td>Assessment and provision of vaccinations, such as for people from key populations, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC</td></tr><tr><td style="white-space:nowrap">DE159<a name="HIV.C-DE159"> </a></td><td>Hepatitis B virus (HBV) and hepatitis C virus (HCV) testing and treatment</td><td>Offer or refer for HBV testing and vaccination and HCV testing and treatment</td></tr><tr><td style="white-space:nowrap">DE160<a name="HIV.C-DE160"> </a></td><td>Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia</td><td>Offer or refer for co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia</td></tr><tr><td style="white-space:nowrap">DE161<a name="HIV.C-DE161"> </a></td><td>Intensified TB case finding and linkage to TB treatment</td><td>Offer or refer for TB case finding and linkage to TB treatment</td></tr><tr><td style="white-space:nowrap">DE162<a name="HIV.C-DE162"> </a></td><td>Provision of isoniazid preventive therapy if person does not have TB</td><td>Offer or refer for provision of isoniazid preventive therapy if person does not have TB</td></tr><tr><td style="white-space:nowrap">DE163<a name="HIV.C-DE163"> </a></td><td>Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology</td><td>Offer or refer for malaria prevention (such as bed nets and prophylaxis), depending on epidemiology</td></tr><tr><td style="white-space:nowrap">DE164<a name="HIV.C-DE164"> </a></td><td>Other support services</td><td>Offer or refer for other support services</td></tr><tr><td style="white-space:nowrap">DE165<a name="HIV.C-DE165"> </a></td><td>Mental health services</td><td>Offer or refer for mental health services</td></tr><tr><td style="white-space:nowrap">DE166<a name="HIV.C-DE166"> </a></td><td>Psychosocial counselling, support and treatment adherence counselling</td><td>Offer or refer for psychosocial counselling, support and treatment adherence counselling</td></tr><tr><td style="white-space:nowrap">DE167<a name="HIV.C-DE167"> </a></td><td>Support for disclosure and partner services</td><td>Offer or refer for support for disclosure and partner services</td></tr><tr><td style="white-space:nowrap">DE168<a name="HIV.C-DE168"> </a></td><td>Legal and social services</td><td>Offer or refer for legal and social services</td></tr><tr><td style="white-space:nowrap">DE169<a name="HIV.C-DE169"> </a></td><td>Services for responding to violence against women</td><td>Offer or refer for services for responding to violence against women, including first-line support and psychosocial support, post-rape care and other support services including shelters, legal services and women and child protection services</td></tr></table></div>
  </text>
  <url value="http://worldhealthorganization.github.io/smart/CodeSystem/HIV.C"/>
  <version value="0.1.0"/>
  <name value="HIV_C"/>
  <title value="HIV.C PrEP visit  CodeSystem"/>
  <status value="draft"/>
  <experimental value="false"/>
  <date value="2023-12-10T23:03:10+00:00"/>
  <publisher value="WHO"/>
  <contact>
    <name value="WHO"/>
    <telecom>
      <system value="url"/>
      <value value="http://who.int"/>
    </telecom>
  </contact>
  <description value="CodeSystem for HIV.C PrEP visit  Data Elements"/>
  <caseSensitive value="false"/>
  <content value="complete"/>
  <count value="169"/>
  <concept>
    <code value="DE1"/>
    <display value="Reason for PrEP visit"/>
    <definition value="Client's reason for the prevention visit"/>
  </concept>
  <concept>
    <code value="DE2"/>
    <display value="First time counselling on PrEP"/>
    <definition value="The client is interested in discussing pre-exposure prophylaxis (PrEP) for the first time"/>
  </concept>
  <concept>
    <code value="DE3"/>
    <display value="Follow-up appointment for PrEP"/>
    <definition value="Client is at a follow-up or refill pre-exposure prophylaxis (PrEP) appointment"/>
  </concept>
  <concept>
    <code value="DE4"/>
    <display value="Restarting PrEP"/>
    <definition value="Client has previously taken pre-exposure prophylaxis (PrEP) and may like to restart taking it"/>
  </concept>
  <concept>
    <code value="DE5"/>
    <display value="Counselling on PEP"/>
    <definition value="Counselling on post-exposure prophylaxis (PEP)"/>
  </concept>
  <concept>
    <code value="DE6"/>
    <display value="Unscheduled visit for side effects"/>
    <definition value="Patient visit for management of side effects related to PrEP"/>
  </concept>
  <concept>
    <code value="DE7"/>
    <display value="3-month PrEP visit"/>
    <definition value="Client is visiting for the recommended 3-month pre-exposure prophylaxis (PrEP) visit"/>
  </concept>
  <concept>
    <code value="DE8"/>
    <display value="Contact with and (suspected) exposure to HIV"/>
    <definition value="The client had suspected or known exposure to HIV"/>
  </concept>
  <concept>
    <code value="DE9"/>
    <display value="Date/time of suspected exposure to HIV"/>
    <definition value="When the suspect exposure to HIV took place"/>
  </concept>
  <concept>
    <code value="DE10"/>
    <display value="Currently on PrEP"/>
    <definition value="The client is currently taking PrEP. Oral pre-exposure prophylaxis (PrEP) of HIV is the use of ARV drugs by people who are not infected with HIV to block the acquisition of HIV."/>
  </concept>
  <concept>
    <code value="DE11"/>
    <display value="PrEP dosing type"/>
    <definition value="Way in which pre-exposure prophylaxis (PrEP) is taken (daily or event-driven)"/>
  </concept>
  <concept>
    <code value="DE12"/>
    <display value="Daily oral PrEP"/>
    <definition value="Pre-exposure prophylaxis (PrEP) is taken every day"/>
  </concept>
  <concept>
    <code value="DE13"/>
    <display value="Event-driven PrEP (2+1+1)"/>
    <definition value="Event-driven pre-exposure prophylaxis (PrEP) is taken on an even-driven basis (2+1+1)"/>
  </concept>
  <concept>
    <code value="DE14"/>
    <display value="Other PrEP dosing type"/>
    <definition value="Other PrEP dosing type"/>
  </concept>
  <concept>
    <code value="DE15"/>
    <display value="Other PrEP dosing type (specify)"/>
    <definition value="Other PrEP dosing type (specify)"/>
  </concept>
  <concept>
    <code value="DE16"/>
    <display value="Used event-driven PrEP for at risk exposures over the past 3 months"/>
    <definition value="Client reports taking ED-PrEP for at risk exposures over a 3-month period"/>
  </concept>
  <concept>
    <code value="DE17"/>
    <display value="Current PrEP regimen"/>
    <definition value="HIV pre-exposure prophylaxis (PrEP) regimen"/>
  </concept>
  <concept>
    <code value="DE18"/>
    <display value="TDF + FTC"/>
    <definition value="Treated with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)"/>
  </concept>
  <concept>
    <code value="DE19"/>
    <display value="TDF"/>
    <definition value="Treated with single-agent tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)"/>
  </concept>
  <concept>
    <code value="DE20"/>
    <display value="TDF + 3TC"/>
    <definition value="Treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)"/>
  </concept>
  <concept>
    <code value="DE21"/>
    <display value="Other TDF-based regimen"/>
    <definition value="Treated with other tenofovir disoproxil fumarate (TDF)-based regimen (oral PrEP)"/>
  </concept>
  <concept>
    <code value="DE22"/>
    <display value="Dapivirine vaginal ring (DVR)"/>
    <definition value="Dapivirine vaginal ring (DVR) for HIV prevention"/>
  </concept>
  <concept>
    <code value="DE23"/>
    <display value="CAB-LA"/>
    <definition value="Long-acting injectable cabotegravir"/>
  </concept>
  <concept>
    <code value="DE24"/>
    <display value="Experience with PrEP"/>
    <definition value="The client's experience in taking PrEP"/>
  </concept>
  <concept>
    <code value="DE25"/>
    <display value="First-time user"/>
    <definition value="The client has never used pre-exposure prophylaxis (PrEP) before (naive)"/>
  </concept>
  <concept>
    <code value="DE26"/>
    <display value="Continuing user"/>
    <definition value="The client has used PrEP before and is continuing to use PrEP"/>
  </concept>
  <concept>
    <code value="DE27"/>
    <display value="Restarting following a period of not taking PrEP"/>
    <definition value="The client is restarting PrEP following a period of not taking PrEP"/>
  </concept>
  <concept>
    <code value="DE28"/>
    <display value="PrEP start date"/>
    <definition value="The date on which the client started or restarted pre-exposure prophylaxis (PrEP)"/>
  </concept>
  <concept>
    <code value="DE29"/>
    <display value="Stopped PrEP"/>
    <definition value="Client stopped taking pre-exposure prophylaxis (PrEP)"/>
  </concept>
  <concept>
    <code value="DE30"/>
    <display value="Date PrEP stopped"/>
    <definition value="Date client stopped taking pre-exposure prophylaxis (PrEP)"/>
  </concept>
  <concept>
    <code value="DE31"/>
    <display value="PEP history"/>
    <definition value="The client's history in taking post-exposure prophylaxis (PEP) for HIV prevention"/>
  </concept>
  <concept>
    <code value="DE32"/>
    <display value="First-time user"/>
    <definition value="The client has never used post-exposure prophylaxis (PEP) before"/>
  </concept>
  <concept>
    <code value="DE33"/>
    <display value="Repeat user"/>
    <definition value="The client has used post-exposure prophylaxis (PEP) before"/>
  </concept>
  <concept>
    <code value="DE34"/>
    <display value="Date(s) of past PEP use"/>
    <definition value="Dates when the client previously used post-exposure prophylaxis (PEP)"/>
  </concept>
  <concept>
    <code value="DE35"/>
    <display value="Date client completes PEP course"/>
    <definition value="Date client completes PEP course"/>
  </concept>
  <concept>
    <code value="DE36"/>
    <display value="Signs of substantial risk of HIV infection"/>
    <definition value="Signs the client is at a substantial risk of HIV infection"/>
  </concept>
  <concept>
    <code value="DE37"/>
    <display value="No condom use during sex with more than one partner in the past 6 months"/>
    <definition value="Recent vaginal or anal sexual intercourse without a condom with more than one partner"/>
  </concept>
  <concept>
    <code value="DE38"/>
    <display value="STI in the past 6 months"/>
    <definition value="A recent history (in the last 6 months) of a sexually transmitted infection (STI ) by laboratory testing, self-report or syndromic STI treatment"/>
  </concept>
  <concept>
    <code value="DE39"/>
    <display value="A sexual partner in the past 6 months had one or more HIV risk factors"/>
    <definition value="A recent sex partner of the client had HIV risk factors"/>
  </concept>
  <concept>
    <code value="DE40"/>
    <display value="PrEP requested by client"/>
    <definition value="Client is requesting PrEP, reflecting a decision-making process has already taken place and suggesting of substantial risk of HIV"/>
  </concept>
  <concept>
    <code value="DE41"/>
    <display value="Pregnancy intention in serodiscordant partnerships"/>
    <definition value="Client's intention or desire in the next year to either become pregnant or prevent a future pregnancy (in serodiscordant partnerships)"/>
  </concept>
  <concept>
    <code value="DE42"/>
    <display value="Yes, I want to become pregnant"/>
    <definition value="Client intends to become pregnant"/>
  </concept>
  <concept>
    <code value="DE43"/>
    <display value="I'm OK either way"/>
    <definition value="Client is not intending to become pregnant, but would not be adverse to becoming pregnant"/>
  </concept>
  <concept>
    <code value="DE44"/>
    <display value="No, I don't want to become pregnant"/>
    <definition value="Client does not intend to become pregnant"/>
  </concept>
  <concept>
    <code value="DE45"/>
    <display value="Unsure"/>
    <definition value="Client is unsure or undecided about her pregnancy intentions"/>
  </concept>
  <concept>
    <code value="DE46"/>
    <display value="Acute HIV infection symptoms"/>
    <definition value="Symptoms that could suggest an acute HIV infection"/>
  </concept>
  <concept>
    <code value="DE47"/>
    <display value="Fever"/>
    <definition value="Client's symptoms include a fever"/>
  </concept>
  <concept>
    <code value="DE48"/>
    <display value="Sore throat"/>
    <definition value="Client's symptoms include a sore throat"/>
  </concept>
  <concept>
    <code value="DE49"/>
    <display value="Aches"/>
    <definition value="Client's symptoms include aches"/>
  </concept>
  <concept>
    <code value="DE50"/>
    <display value="Pains"/>
    <definition value="Client's symptoms include pains"/>
  </concept>
  <concept>
    <code value="DE51"/>
    <display value="Swollen glands"/>
    <definition value="Client's symptoms include swollen glands"/>
  </concept>
  <concept>
    <code value="DE52"/>
    <display value="Mouth sores"/>
    <definition value="Client's symptoms include a mouth sores"/>
  </concept>
  <concept>
    <code value="DE53"/>
    <display value="Headaches"/>
    <definition value="Client's symptoms include a headaches"/>
  </concept>
  <concept>
    <code value="DE54"/>
    <display value="Rash"/>
    <definition value="Client's symptoms include a rash"/>
  </concept>
  <concept>
    <code value="DE55"/>
    <display value="Sex partner's HIV treatment status"/>
    <definition value="Treatment adherence of client's sex partner for partners that are HIV-positive"/>
  </concept>
  <concept>
    <code value="DE56"/>
    <display value="Not on ART"/>
    <definition value="Sex partner is HIV-positive and not on ART"/>
  </concept>
  <concept>
    <code value="DE57"/>
    <display value="On ART less than 6 months"/>
    <definition value="Sex partner is HIV-positive and is on ART less than 6 months. ART may take up to 6 months to suppress viral load. In studies of serodiscordant couples, pre-exposure prophylaxis (PrEP) has provided a useful bridge to full viral suppression by the partner during that time."/>
  </concept>
  <concept>
    <code value="DE58"/>
    <display value="Partner has suspected low adherence to ART"/>
    <definition value="Sex partner is HIV-positive and is suspected to have low adherence to ART. There have been gaps in the partner's treatment adherence or the couple is not communicating openly about treatment adherence and viral load test results."/>
  </concept>
  <concept>
    <code value="DE59"/>
    <display value="Partner is not virally suppressed"/>
    <definition value="Sex partner is HIV-positive and not virally suppressed"/>
  </concept>
  <concept>
    <code value="DE60"/>
    <display value="Partner is virally suppressed and has been on ART for 6 months or more"/>
    <definition value="Sex partner is HIV-positive and virally suppressed with 6 months or more on ART"/>
  </concept>
  <concept>
    <code value="DE61"/>
    <display value="Suitable for PrEP"/>
    <definition value="The client is suitable for PrEP"/>
  </concept>
  <concept>
    <code value="DE62"/>
    <display value="Offered PrEP"/>
    <definition value="After being evaluated as suitable for PrEP, the client was offered PrEP"/>
  </concept>
  <concept>
    <code value="DE63"/>
    <display value="Screenings and diagnostics for PrEP users"/>
    <definition value="Listing of tests for clients on or starting pre-exposure prophylaxis (PrEP) that may be recommended or should be considered"/>
  </concept>
  <concept>
    <code value="DE64"/>
    <display value="Serum creatinine test"/>
    <definition value="Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min)"/>
  </concept>
  <concept>
    <code value="DE65"/>
    <display value="Hepatitis B test"/>
    <definition value="Hepatitis B test recommended for client"/>
  </concept>
  <concept>
    <code value="DE66"/>
    <display value="Hepatitis C test"/>
    <definition value="Hepatitis C test recommended for client"/>
  </concept>
  <concept>
    <code value="DE67"/>
    <display value="Syphilis test"/>
    <definition value="Syphilis test recommended for client"/>
  </concept>
  <concept>
    <code value="DE68"/>
    <display value="Other screening for STIs"/>
    <definition value="Other STI screening recommended for client"/>
  </concept>
  <concept>
    <code value="DE69"/>
    <display value="Pregnancy testing"/>
    <definition value="Pregnancy testing for client"/>
  </concept>
  <concept>
    <code value="DE70"/>
    <display value="Review vaccination history"/>
    <definition value="Review vaccination history recommended for client"/>
  </concept>
  <concept>
    <code value="DE71"/>
    <display value="Serum creatinine test date"/>
    <definition value="Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min)"/>
  </concept>
  <concept>
    <code value="DE72"/>
    <display value="Serum creatinine test result"/>
    <definition value="Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min)."/>
  </concept>
  <concept>
    <code value="DE73"/>
    <display value="Date medications dispensed"/>
    <definition value="Date the client was dispensed medications"/>
  </concept>
  <concept>
    <code value="DE74"/>
    <display value="Date medications prescribed"/>
    <definition value="Date the client was prescribed medications"/>
  </concept>
  <concept>
    <code value="DE75"/>
    <display value="Medications prescribed"/>
    <definition value="Medications the client was prescribed"/>
  </concept>
  <concept>
    <code value="DE76"/>
    <display value="PrEP for HIV prevention"/>
    <definition value="Client was prescribed pre-exposure prophylaxis (PrEP) for HIV prevention"/>
  </concept>
  <concept>
    <code value="DE77"/>
    <display value="PEP for HIV prevention"/>
    <definition value="Client was prescribed post-exposure prophylaxis (PEP) for HIV prevention"/>
  </concept>
  <concept>
    <code value="DE78"/>
    <display value="Other"/>
    <definition value="Client was prescribed other medications"/>
  </concept>
  <concept>
    <code value="DE79"/>
    <display value="Other (specify)"/>
    <definition value="Client was prescribed other medications (specify)"/>
  </concept>
  <concept>
    <code value="DE80"/>
    <display value="PrEP product prescribed"/>
    <definition value="PrEP product that the client was prescribed"/>
  </concept>
  <concept>
    <code value="DE81"/>
    <display value="Oral PrEP"/>
    <definition value="Client was prescribed oral PrEP"/>
  </concept>
  <concept>
    <code value="DE82"/>
    <display value="Dapivirine vaginal ring (DVR)"/>
    <definition value="Client was prescribed dapivirine vaginal ring (DVR)"/>
  </concept>
  <concept>
    <code value="DE83"/>
    <display value="CAB-LA"/>
    <definition value="Client was prescribed long-acting cabotegravir (CAB-LA)"/>
  </concept>
  <concept>
    <code value="DE84"/>
    <display value="Other"/>
    <definition value="Client was prescribed other PrEP product"/>
  </concept>
  <concept>
    <code value="DE85"/>
    <display value="Other (specify)"/>
    <definition value="Client was prescribed other PrEP product (specify)"/>
  </concept>
  <concept>
    <code value="DE86"/>
    <display value="Date PrEP prescribed"/>
    <definition value="Date client was prescribed PrEP, including initial prescription and repeats"/>
  </concept>
  <concept>
    <code value="DE87"/>
    <display value="Date PrEP dispensed"/>
    <definition value="Date client was dispensed PrEP"/>
  </concept>
  <concept>
    <code value="DE88"/>
    <display value="Volume of PrEP product prescribed/dispensed"/>
    <definition value="Volume of PrEP product the client was prescribed or dispensed (for example, number of pills, number of devices)"/>
  </concept>
  <concept>
    <code value="DE89"/>
    <display value="Date PEP prescribed"/>
    <definition value="Date the client was prescribed PEP"/>
  </concept>
  <concept>
    <code value="DE90"/>
    <display value="Date PEP course completion"/>
    <definition value="Date client completes PEP course"/>
  </concept>
  <concept>
    <code value="DE91"/>
    <display value="Preferred PEP backbone regimen"/>
    <definition value="Preferred backbone regimen for PEP"/>
  </concept>
  <concept>
    <code value="DE92"/>
    <display value="TDF + 3TC"/>
    <definition value="Preferred backbone containing tenofovir disoproxil fumarate and lamivudine"/>
  </concept>
  <concept>
    <code value="DE93"/>
    <display value="TDF + FTC"/>
    <definition value="Preferred backbone containing tenofovir disoproxil fumarate and emtricitabine"/>
  </concept>
  <concept>
    <code value="DE94"/>
    <display value="AZT + 3TC"/>
    <definition value="Preferred backbone containing zidovudine and lamivudine"/>
  </concept>
  <concept>
    <code value="DE95"/>
    <display value="Alternative PEP backbone regimen"/>
    <definition value="Alternative backbone regimen for PEP"/>
  </concept>
  <concept>
    <code value="DE96"/>
    <display value="ABC + 3TC"/>
    <definition value="Alternative backbone containing abacavir and lamivudine"/>
  </concept>
  <concept>
    <code value="DE97"/>
    <display value="TDF + 3TC"/>
    <definition value="Alternative backbone containing tenofovir disoproxil fumarate and lamivudine"/>
  </concept>
  <concept>
    <code value="DE98"/>
    <display value="TDF + FTC"/>
    <definition value="Alternative backbone containing tenofovir disoproxil fumarate and emtricitabine"/>
  </concept>
  <concept>
    <code value="DE99"/>
    <display value="Preferred third PEP drug"/>
    <definition value="Preferred third drug for PEP"/>
  </concept>
  <concept>
    <code value="DE100"/>
    <display value="DTG"/>
    <definition value="Preferred third drug of dolutegravir"/>
  </concept>
  <concept>
    <code value="DE101"/>
    <display value="Alternative third PEP drug"/>
    <definition value="Alternative third drug for PEP"/>
  </concept>
  <concept>
    <code value="DE102"/>
    <display value="ATV/r"/>
    <definition value="Alternative third drug of atazanavir/ritonavir (ATV/r)"/>
  </concept>
  <concept>
    <code value="DE103"/>
    <display value="DRV/r"/>
    <definition value="Alternative third drug of darunavir/ritonavir (DRV/r)"/>
  </concept>
  <concept>
    <code value="DE104"/>
    <display value="LPV/r"/>
    <definition value="Alternative third drug of lopinavir/ritonavir (LPV/r)"/>
  </concept>
  <concept>
    <code value="DE105"/>
    <display value="RAL"/>
    <definition value="Alternative third drug of raltegravir (RAL)"/>
  </concept>
  <concept>
    <code value="DE106"/>
    <display value="Estimated creatinine clearance"/>
    <definition value="Estimated creatinine clearance of the client returned from lab in mL/min"/>
  </concept>
  <concept>
    <code value="DE107"/>
    <display value="Sex factor for estimating creatinine clearance"/>
    <definition value="Value used for gender for calculating creatinine clearance if required. For transgender populations, the sex at birth is used in the Cockcroft-Gault equation if the person is not using hormone therapy; among transgender populations using hormone therapy for more than three months, the current gender can be used."/>
  </concept>
  <concept>
    <code value="DE108"/>
    <display value="Male"/>
    <definition value="Male client"/>
  </concept>
  <concept>
    <code value="DE109"/>
    <display value="Female"/>
    <definition value="Female client"/>
  </concept>
  <concept>
    <code value="DE110"/>
    <display value="Estimated creatinine clearance (Cockcroft–Gault equation)"/>
    <definition value="If the laboratory does not have the capacity to estimate creatinine clearance, the provider can use the Cockcroft–Gault equation to calculate estimated creatinine clearance based on measured serum creatinine, the client’s sex at birth, age and estimated lean body weight."/>
  </concept>
  <concept>
    <code value="DE111"/>
    <display value="Date of sample collection"/>
    <definition value="Date when the specimen was collected"/>
  </concept>
  <concept>
    <code value="DE112"/>
    <display value="Contraindications to PrEP usage"/>
    <definition value="Listing of contraindications to pre-exposure prophylaxis (PrEP)"/>
  </concept>
  <concept>
    <code value="DE113"/>
    <display value="Tenofovir disoproxil fumarate (TDF) allergy or contraindication"/>
    <definition value="Allergy to pre-exposure prophylaxis (PrEP) tenofovir disoproxil fumarate (TDF)"/>
  </concept>
  <concept>
    <code value="DE114"/>
    <display value="HIV-positive"/>
    <definition value="Client is HIV-positive"/>
  </concept>
  <concept>
    <code value="DE115"/>
    <display value="Low estimated creatinine clearance"/>
    <definition value="Estimated creatinine clearance of less than 60 ml/min (if known)"/>
  </concept>
  <concept>
    <code value="DE116"/>
    <display value="Acute HIV infection symptoms"/>
    <definition value="Symptoms that could suggest an acute HIV infection"/>
  </concept>
  <concept>
    <code value="DE117"/>
    <display value="Probable recent exposure to HIV"/>
    <definition value="When the client is reported to have had probable recent exposure to HIV"/>
  </concept>
  <concept>
    <code value="DE118"/>
    <display value="Other allergy or contraindication to a medicine in the PrEP regimen"/>
    <definition value="Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen"/>
  </concept>
  <concept>
    <code value="DE119"/>
    <display value="Other allergy or contraindication to a medicine in the PrEP regimen (specify)"/>
    <definition value="Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen (specify)"/>
  </concept>
  <concept>
    <code value="DE120"/>
    <display value="Prescribed PrEP at initial visit"/>
    <definition value="Client was prescribed pre-exposure prophylaxis (PrEP) on a first visit"/>
  </concept>
  <concept>
    <code value="DE121"/>
    <display value="Number of days prescribed"/>
    <definition value="Days of medication client has been prescribed"/>
  </concept>
  <concept>
    <code value="DE122"/>
    <display value="PrEP regimen prescribed"/>
    <definition value="HIV pre-exposure prophylaxis (PrEP) regimen prescribed"/>
  </concept>
  <concept>
    <code value="DE123"/>
    <display value="Adherence counselling provided"/>
    <definition value="Whether adherence counselling was provided"/>
  </concept>
  <concept>
    <code value="DE124"/>
    <display value="Date/time of follow-up appointment"/>
    <definition value="Date the client is to return for monitoring, re-supply, or any other reason"/>
  </concept>
  <concept>
    <code value="DE125"/>
    <display value="Type of follow-up appointment"/>
    <definition value="Type of follow-up appointment for testing services"/>
  </concept>
  <concept>
    <code value="DE126"/>
    <display value="Retesting for HIV"/>
    <definition value="Retesting follow-up appointment"/>
  </concept>
  <concept>
    <code value="DE127"/>
    <display value="Follow-up appointment for PrEP"/>
    <definition value="Retesting follow-up appointment"/>
  </concept>
  <concept>
    <code value="DE128"/>
    <display value="Other"/>
    <definition value="Other reason for the follow-up appointment"/>
  </concept>
  <concept>
    <code value="DE129"/>
    <display value="Other (specify)"/>
    <definition value="Other reason for the follow-up appointment (specify)"/>
  </concept>
  <concept>
    <code value="DE130"/>
    <display value="Linked to enrolment in care and ART initiation"/>
    <definition value="Linkage made from HIV testing to enrolment in care following an HIV diagnosis"/>
  </concept>
  <concept>
    <code value="DE131"/>
    <display value="Prevention services offered and referrals"/>
    <definition value="Offer or refer to prevention services"/>
  </concept>
  <concept>
    <code value="DE132"/>
    <display value="Male and female condoms and condom-compatible lubricants offered"/>
    <definition value="Offer male and female condoms and condom-compatible lubricants"/>
  </concept>
  <concept>
    <code value="DE133"/>
    <display value="Voluntary medical male circumcision (VMMC) referral"/>
    <definition value="Offer referral for VMMC services"/>
  </concept>
  <concept>
    <code value="DE134"/>
    <display value="Harm reduction for people who inject drugs"/>
    <definition value="Offer or refer to harm reduction for people who inject drugs (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management) services"/>
  </concept>
  <concept>
    <code value="DE135"/>
    <display value="Behavioural interventions to support risk reduction"/>
    <definition value="Offer or refer to services for behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations"/>
  </concept>
  <concept>
    <code value="DE136"/>
    <display value="Date provided condoms"/>
    <definition value="Date client was provided with condoms"/>
  </concept>
  <concept>
    <code value="DE137"/>
    <display value="Condoms distributed"/>
    <definition value="Number of condoms given to the client, if any were distributed"/>
  </concept>
  <concept>
    <code value="DE138"/>
    <display value="Condom type"/>
    <definition value="Type of condom provided to client"/>
  </concept>
  <concept>
    <code value="DE139"/>
    <display value="Male condom"/>
    <definition value="Male condoms were provided to the client"/>
  </concept>
  <concept>
    <code value="DE140"/>
    <display value="Female condom"/>
    <definition value="Female condoms were provided to the client"/>
  </concept>
  <concept>
    <code value="DE141"/>
    <display value="HIV self-test kits accepted"/>
    <definition value="Whether any HIV self-test kits were given to the client"/>
  </concept>
  <concept>
    <code value="DE142"/>
    <display value="Number of HIV self-test kits distributed"/>
    <definition value="Number of HIV self-test kits distributed to the client"/>
  </concept>
  <concept>
    <code value="DE143"/>
    <display value="HIV self-test distributed for use by"/>
    <definition value="Whom the client plans to give the HIV self-test kit (self, sexual partner, social contact, etc.)"/>
  </concept>
  <concept>
    <code value="DE144"/>
    <display value="Self"/>
    <definition value="Client plans to use the self-test kit"/>
  </concept>
  <concept>
    <code value="DE145"/>
    <display value="Family member"/>
    <definition value="Client plans to give the self-test kit to a family member to use"/>
  </concept>
  <concept>
    <code value="DE146"/>
    <display value="Drug-injecting partner"/>
    <definition value="Client plans to give the self-test kit to a drug-injecting partner"/>
  </concept>
  <concept>
    <code value="DE147"/>
    <display value="Sexual partner"/>
    <definition value="Client plans to give the self-test kit to a sexual partner"/>
  </concept>
  <concept>
    <code value="DE148"/>
    <display value="Social contact"/>
    <definition value="Client plans to give the self-test kit to a social contact"/>
  </concept>
  <concept>
    <code value="DE149"/>
    <display value="Sexual and reproductive health integrated services"/>
    <definition value="Offer or refer to sexual and reproductive health services"/>
  </concept>
  <concept>
    <code value="DE150"/>
    <display value="Contraception and family planning"/>
    <definition value="Offer contraception and family planning services"/>
  </concept>
  <concept>
    <code value="DE151"/>
    <display value="Check pregnancy status"/>
    <definition value="Check woman's pregnancy status"/>
  </concept>
  <concept>
    <code value="DE152"/>
    <display value="Prevent mother-to-child transmission"/>
    <definition value="Offer services (counselling) to help prevent of mother-to-child transmission"/>
  </concept>
  <concept>
    <code value="DE153"/>
    <display value="Cervical cancer screening and treatment"/>
    <definition value="Offer cervical cancer screening and treatment services"/>
  </concept>
  <concept>
    <code value="DE154"/>
    <display value="Anal cancer screening (for men who have sex with men)"/>
    <definition value="Offer anal cancer screening (for men who have sex with men) services"/>
  </concept>
  <concept>
    <code value="DE155"/>
    <display value="STI testing and treatment"/>
    <definition value="Offer STI testing and treatment services"/>
  </concept>
  <concept>
    <code value="DE156"/>
    <display value="HIV testing for partners and biological children"/>
    <definition value="Offer testing for all partners and biological children of positive cases (includes partner services and index case testing), as well as partners and social contacts of people from key populations, where appropriate"/>
  </concept>
  <concept>
    <code value="DE157"/>
    <display value="Offer other clinical services"/>
    <definition value="Other clinical services offered or referrals given to the client"/>
  </concept>
  <concept>
    <code value="DE158"/>
    <display value="Assessment and provision of vaccinations"/>
    <definition value="Assessment and provision of vaccinations, such as for people from key populations, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC"/>
  </concept>
  <concept>
    <code value="DE159"/>
    <display value="Hepatitis B virus (HBV) and hepatitis C virus (HCV) testing and treatment"/>
    <definition value="Offer or refer for HBV testing and vaccination and HCV testing and treatment"/>
  </concept>
  <concept>
    <code value="DE160"/>
    <display value="Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia"/>
    <definition value="Offer or refer for co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia"/>
  </concept>
  <concept>
    <code value="DE161"/>
    <display value="Intensified TB case finding and linkage to TB treatment"/>
    <definition value="Offer or refer for TB case finding and linkage to TB treatment"/>
  </concept>
  <concept>
    <code value="DE162"/>
    <display value="Provision of isoniazid preventive therapy if person does not have TB"/>
    <definition value="Offer or refer for provision of isoniazid preventive therapy if person does not have TB"/>
  </concept>
  <concept>
    <code value="DE163"/>
    <display value="Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology"/>
    <definition value="Offer or refer for malaria prevention (such as bed nets and prophylaxis), depending on epidemiology"/>
  </concept>
  <concept>
    <code value="DE164"/>
    <display value="Other support services"/>
    <definition value="Offer or refer for other support services"/>
  </concept>
  <concept>
    <code value="DE165"/>
    <display value="Mental health services"/>
    <definition value="Offer or refer for mental health services"/>
  </concept>
  <concept>
    <code value="DE166"/>
    <display value="Psychosocial counselling, support and treatment adherence counselling"/>
    <definition value="Offer or refer for psychosocial counselling, support and treatment adherence counselling"/>
  </concept>
  <concept>
    <code value="DE167"/>
    <display value="Support for disclosure and partner services"/>
    <definition value="Offer or refer for support for disclosure and partner services"/>
  </concept>
  <concept>
    <code value="DE168"/>
    <display value="Legal and social services"/>
    <definition value="Offer or refer for legal and social services"/>
  </concept>
  <concept>
    <code value="DE169"/>
    <display value="Services for responding to violence against women"/>
    <definition value="Offer or refer for services for responding to violence against women, including first-line support and psychosocial support, post-rape care and other support services including shelters, legal services and women and child protection services"/>
  </concept>
</CodeSystem>